Pembrolizumab/Chemo With or Without Bevacizumab Has Potential as New SOC in Metastatic Cervical Cancer
Nicoletta Colombo, MD, PhD, discusses the practice-changing data to emerge from KEYNOTE-826 and the next steps for the pembrolizumab plus chemotherapy with or without bevacizumab regimen in patients with cervical cancer.
Sotigalimab Plus Nivolumab Shows Encouraging Activity in Anti–PD-1 Refractory Melanoma
The combination of sotigalimab and nivolumab elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial.
Teclistamab/Daratumumab Combo Delivers Promising ORR in Heavily Pretreated Relapsed/Refractory Myeloma
Paula Rodriguez-Otero, MD, PhD, discusses the rationale, design, and findings of the phase 1b TRIMM-2 trial assessing subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma.
Cheng Explores the Evolution of Immunotherapy in the Cancer Field
Jonathan D. Cheng, MD, discusses the various categories of immuno-oncology, including checkpoint inhibitors, immunotherapy combinations, and TKIs, that are moving the modality forward.
Histology-Specific Trials and Drug Development Strategy Pave the Path to Progress in Soft Tissue Sarcoma
William D. Tap, MD, discusses the key challenges faced in the treatment of patients with soft tissue sarcoma and efforts being made to overcome them.
Talquetamab/Daratumumab Shows Promise in Heavily Pretreated Myeloma, Warranting Further Investigation
Ajai Chari, MD, discusses the safety and efficacy of talquetamab plus daratumumab in heavily pretreated patients with multiple myeloma, initial data from phase 1b TRIMM-2 trial, and the potential to move the combination into earlier lines of therapy.
Modakafusp Alfa Elicits Single-Agent Activity, Represents a Novel Option in Relapsed/Refractory Myeloma
Dan Vogl, MD, MSCE, discusses the unique mechanism of action of modakafusp alfa and the updated results from an expansion cohort in patients with relapsed/refractory multiple myeloma.
Upifitamab Rilsodotin Has Potential to Address Unmet Need in Recurrent Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the unmet needs for patients with ovarian cancer and the clinical trials that seeking to address those needs, including the ADC upifitamab rilsodotin.
Subcutaneous Epcoritamab Demonstrates Early Activity, Favorable Tolerability in CLL
Subcutaneous epcoritamab demonstrated early activity and favorable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia and high-risk features.
Immunotherapy Outcomes in HPV-Associated Head and Neck Cancer Fuel Investigative Efforts
Robert L. Ferris, MD, PhD, discusses the current standard of care for patients with head and neck cancer, the role of HPV in treatment decisions, and the need to personalize therapy for patients.
MB-106 Elicits Durable Responses and Demonstrates Tolerable Safety Profile in DLBCL, MCL, Follicular Lymphoma
Mazyar Shadman, MD, MPH, discusses the utility of MB-106 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia.
Adagrasib With or Without Cetuximab Produces Encouraging Clinical Activity in KRAS G12C–Mutant CRC
Jared Weiss, MD, sheds light on the exploration of adagrasib as a monotherapy and in combination with cetuximab in patients with KRAS G12C–mutated metastatic colorectal cancer, key findings from the KRYSTAL-1 study, and next steps for research.
Trastuzumab Deruxtecan Maintains PFS Benefit Across Subgroups in HER2+ Metastatic Breast Cancer
Sara Hurvitz, MD, discusses the findings from the subgroup analysis of the DESTINY-Breast03 trial, and future research directions for trastuzumab deruxtecan.
Polatuzumab Vedotin Plus R-CHP Emerges as Potential New Standard for Newly Diagnosed DLBCL
John M. Burke, MD, highlights the benefits derived with polatuzumab vedotin plus R-CHP and projects the next steps for the regimen.
Pembrolizumab Plus Enzalutamide Continues to Produce Antitumor Activity in Abiraterone Acetate-Pretreated mCRPC
The combination of pembrolizumab and enzalutamide continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who were previously treated with abiraterone acetate, according to data from cohort C of the phase 1b/2 KEYNOTE-365 trial.
Olaparib/Temozolomide Shows Encouraging Efficacy, Manageable Safety in Uterine Leiomyosarcoma
In patients with advanced uterine leiomyosarcoma whose tumors harbor a BRCA-like phenotype, the combination of olaparib with temozolomide could represent a new standard of care.
Allison Shares His Path to Groundbreaking Achievements in Immuno-Oncology
James P. Allison, PhD, permanently etched his legacy into immuno-oncology with the development of ipilimumab, work that helped him win a Giants of Cancer Care® award for Scientific Advances in 2014.
Lipson Sheds Light on the Evolving Role of ctDNA in the Realm of Melanoma
Evan J. Lipson, MD, discusses the role of ctDNA in the neoadjuvant, adjuvant, and metastatic settings in the realm of melanoma, remaining questions with this marker, and future directions to optimize its use in this disease.
Emerging Data With KO-539 and Other Menin Inhibitors Generate Excitement in AML
Naval Daver, MD, discusses he encouraging early data that has been reported with KO-539 and other menin inhibitors in acute myeloid leukemia, data presented with novel KO-539 combinations in this disease, and next steps for research.
Surgical Resectability Remains Crucial in Determining Treatment Strategy in Liver-Only Metastatic CRC
Early identification of patients with liver-only metastatic colorectal cancer who are eligible for resection is crucial to determining their course of treatment and what role modalities like chemotherapy will play in their treatment strategy.
Hypoxic Storage Could Extend Red Blood Cell Life, Thereby Reduce Transfusion Frequency in Hematologic Malignancies
Steven L. Spitalnik, MD, discusses the evolution of red blood cell storage and the potential impact the Hemanext storage technique could have for patients with hematologic malignancies.
Real-World Data Underscores Efficacy of Durvalumab in NSCLC
Real-world data from the PACIFIC-R trial evaluating durvalumab following chemoradiotherapy in patients with stage III, unresectable non–small cell lung cancer provide evidence supporting the agent’s efficacy in this population, solidifying its role as a standard-of-care treatment
Enrollment in Histologically-Specific Trials Improves Outcomes in Soft Tissue Sarcoma
Elise Nassif, MD, discusses the evolving standard of care for patients with soft tissue sarcoma and the benefits of early phase inclusion, as well as histotype testing for this population.
Hypoxic Blood May Improve Outcomes for Patients With MDS Requiring Transfusions
Paul M. Ness, MD, discusses the goal of the Hemanext ONE® blood storage system and the potential benefit of this approach for those with myelodysplastic syndrome and other conditions that require transfusions.
MRD-Guided Treatment Represents the Future in CLL
William G. Wierda, MD, PhD, discussed the results of the phase 2 CAPTIVATE trial and the phase 1/2 TRANSCEND CLL 004 trial, and looked ahead to what the future holds for MRD in patients with CLL.
Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma
Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.
Ribociclib/Everolimus Elicits Responses in Dedifferentiated Liposarcoma
Margaret von Mehren, MD, discusses the value of ribociclib plus everolimus for patients with dedifferentiated liposarcoma, and how further research will be focused on biomarker analysis.
The Evolving Role of Prognostic Markers for CLL in the Era of Novel Agents
Deborah M. Stephens, DO, discusses her approach to treating a patients with chronic lymphocytic leukemia, how CAR T-cell therapy may fit into the treatment paradigm, and the numerous trials that have shown promise in this space.
Retifanlimab Shows Promising Antitumor Activity in Advanced Endometrial Cancer
Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.
Hochster Shares Best Practices on Molecular Markers and Sequencing in Gastric Cancer
Howard S. Hochster, MD, discusses molecular markers for patients with gastric cancer, using gene expression profiles as biomarkers, and choosing between anti–PD-1 and anti–CTLA-4 agents.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512